Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Inhibitors >  Mitogen-activated protein kinase (MAPK) >  Raf inhibitors >  Encorafenib (LGX818)

Encorafenib (LGX818)

Basic information Safety Supplier Related

Encorafenib (LGX818) Basic information

Product Name:
Encorafenib (LGX818)
Synonyms:
  • LGX 818
  • LGX818
  • LGX-818
  • CS-1037
  • methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate
  • (S)-Methyl [1-[[4-[3-[5-chloro-2-fluoro-3-(methylsulfonamido)phenyl]-1-isopropyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate
  • Encorafenib
  • Encorafenib (LGX818)
CAS:
1269440-17-6
MF:
C22H27ClFN7O4S
MW:
540.01
Product Categories:
  • Inhibitors
Mol File:
1269440-17-6.mol
More
Less

Encorafenib (LGX818) Chemical Properties

Melting point:
184-185°C
Density 
1.45±0.1 g/cm3(Predicted)
storage temp. 
-20°C Freezer, Under inert atmosphere
solubility 
DMSO (Slightly), Methanol (Slightly)
pka
5.94±0.10(Predicted)
form 
Solid
color 
White to Off-White
More
Less

Encorafenib (LGX818) Usage And Synthesis

Description

Encorafenib (LGX818) is a new-generation BRAF inhibitor that is under evaluation in clinical trials. However, the underlying mechanism remains to be elucidated. Here we show that LGX818 potently decreased ERK phosphorylation and inhibited proliferation in BRAFV600E melanoma cell lines. Moreover, LGX818 downregulated CyclinD1 in a glycogen synthase kinase 3β-independent manner and induced cell cycle arrest in the G1 phase.

Uses

LGX 818 is potent and selective BRAFV600E kinase inhibitor and can be used for the treatment of proliferative diseases such as solid tumor diseases.

brand name

Braftovi

General Description

Class: dual threonine/tyrosine kinase; Treatment: melanoma with BRAFV600E/K; Oral bioavailability = 85%; Elimination half-life = 6 h; Protein binding = 86%

Biological Activity

Encorafenib (LGX818) is a highly potent RAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing B-RAF(V600E) with EC50 of 4 nM. Phase 3.

Pharmacokinetics

Encorafenib shows an oral bioavailability of 85% and a half-life of 6 h. It is administered orally once a day (450 mg), whereas the other two dabrafenib and vemurafenib are taken twice a day (Table 2, Section 10.1). The primary metabolic pathway is N-dealkylation, with CYP3A4 as the main contributor (Fig. 1).

Clinical Use

Encorafenib (LGX818) is a new-generation BRAF inhibitor. It is currently under investigation in clinical trials for the treatment of BRAF mutant metastatic melanoma patients . LGX818 induces sustained mitogen-activated protein kinase (MAPK) pathway inhibition and has selective anti-proliferative and apoptotic activity in cells expressing BRAFV600E. However, the mechanism by which LGX818 suppresses BRAF mutant melanoma cell proliferation has not been thoroughly investigated.

target

B-RAF(V600E)

References

[1] stuart d d, li n, poon d j, et al. preclinical profile of lgx818: a potent and selective raf kinase inhibitor. cancer research, 2012, 72(8 supplement): 3790.
[2] huang t, karsy m, zhuge j, et al. b-raf and the inhibitors: from bench to bedside. j hematol oncol, 2013, 6(1): 30.

Encorafenib (LGX818)Supplier

ChengDu TongChuangYuan Pharmaceutical Co.Ltd Gold
Tel
028-83379370 13880556291
Email
tcy@tcypharm.com
WUHAN SUN-SHINE BIO-TECHNOLOGY Co., Ltd.
Tel
17702719238 17702719238
Email
sales@sun-shinechem.com
Dalian Meilun Biotech Co., Ltd.
Tel
0411-62910999 13889544652
Email
sales@meilune.com
Shanghai Topbiochem Technology Co., Ltd
Tel
021-58170097
Email
info@topbiochem.com
Haoyuan Chemexpress Co., Ltd.
Tel
021-58950125
Email
info@chemexpress.com